Skip to main content
Two female researchers testing vials in a lab)

R&D Haematology


CSL Behring remains focused on easing the burden of care and improving the lives of patients with rare bleeding disorders. Additionally, we are undertaking exciting research and development efforts to explore new indications in haematology as well as novel therapeutics in haemostasis and thrombosis. We have made major advancements in haemophilia A and B in recent years with the launches of our internally developed family of novel recombinant coagulation factor medicines. Our haemophilia research strategy is based on maximising the value and performance of our existing coagulation therapies and developing new protein-based therapies to treat bleeding disorders and increase the quality of life for patients.

Hand holding a pipet cropped

We are working towards improving the quality of life for Haemophilia B patients by evaluating the possibility of extending the dosing intervals from 14 to 21 days. A Phase 3 extension study (PROLONG-9FP) is underway and global regulatory submissions to gain approval for the extended dosing regimen are planned for 2020.

Our commitment to remain at the forefront of innovation is stronger than ever. The acquisition of Calimmune Inc., introduced a new ex vivo haematopoietic stem cell gene therapy (CAL-H/CSL200) for the treatment of sickle cell disease (SCD) into our haematology and thrombosis pipeline. Calimmune’s proprietary platform technologies also have the potential to develop new medicines for a wide range of other rare diseases that complement CSL’s product portfolio and expertise. Complementing the CSL200 program is another exciting program in SCD, CSL889. The CSL889 is plasma derived Hemopexin, an important endogenous molecule whose levels are decreased in patients with sickle cell disease, for treatment of acute vaso-occlusive crisis, a severe and painful complication in SCD patients. Clinical trials using CSL200 and CSL889 are anticipated to start in 2020 and 2021 respectively.